GlycoTARGET – Campusa: Funding by La Caixa Foundation
- An international consortium led by CIC bioGUNE has secured funding from teh 'la Caixa' Foundation to develop novel cancer immunotherapies targeting glycans, complex sugar structures, on cancer cells.
- The GlycoTARGET project, uniting institutions in Spain adn Portugal, aims to overcome longstanding challenges in cancer immunotherapy by focusing on glycans.
- "The project seeks to overcome the immunogenicity barriers that for years have limited new therapies and, at the same time, explore the true scope of glycans and other...
GlycoTARGET Project receives Funding to Advance cancer immunotherapy
Table of Contents
An international consortium led by CIC bioGUNE has secured funding from teh ‘la Caixa’ Foundation to develop novel cancer immunotherapies targeting glycans, complex sugar structures, on cancer cells.
Project Overview: Harnessing Glycans for Cancer Treatment
The GlycoTARGET project, uniting institutions in Spain adn Portugal, aims to overcome longstanding challenges in cancer immunotherapy by focusing on glycans. These complex carbohydrates, often overlooked as immunological targets, are abundant on the surface of cancer cells. The project will leverage advanced nanotechnology to transform these glycans into viable therapeutic targets and boost the immune system’s ability to recognize and destroy cancer.
“The project seeks to overcome the immunogenicity barriers that for years have limited new therapies and, at the same time, explore the true scope of glycans and other complex antigens as possible immunological targets,” explained edurne Rujas, the principal researcher at the University of the Basque Country (EHU).
Funding and Collaboration
The ‘la Caixa’ Foundation’s financial support, awarded through the CaixaResearch call, underscores its commitment to high-quality biomedical research and the integration of basic and translational science. The funding will facilitate both ex vivo (laboratory) and in vivo (animal) studies, allowing researchers to refine adjuvants – substances that enhance immune responses – and thoroughly evaluate the effectiveness of the new therapies.
This project exemplifies the power of international collaboration, combining the scientific leadership of CIC bioGUNE with the complementary expertise of institutions across Spain and Portugal. This collaborative approach is expected to accelerate the growth of innovative solutions in the fight against cancer.
Researcher Profile: Edurne rujas
Edurne Rujas Díez is an Ikerbasque researcher affiliated with the Faculty of Pharmacy at the University of the basque Country (EHU). Her work focuses on the Pharmacy and Pharmaceutical Technology area within the Department of Pharmacy and Food Sciences.